About Joslin | Patient Care | Supporting Joslin
The Blackwell lab studies how cells defend against metabolic stresses, how these stress defenses are regulated, and how these mechanisms influence aging. These protective mechanisms hold great promise for maintaining the functions of various tissues and promoting healthy longevity.
Bonner-Weir is a Senior Investigator (Joslin) and Professor of Medicine (Harvard
Medical School). She is or was on the editorial boards of the American Journal
of Physiology, Journal of Biological Chemistry, Endocrinology, Cell Transplant,
and Diabetes. She is or was a member of grant review panels for the NIH,
Juvenile Diabetes Research Foundation, the American Diabetes Association, the
California Institute of Regenerative Medicine, and the European Research
Research is conducted predominantly as part of the research team of the Beetham Eye Institute. Research activities are concentrated as Clinical co-investigator and visual function examiner in National Eye Institute sponsored clinical trials of diabetic retinopathy, studies sponsored by major pharmaceutical companies, and ocular telemedicine.
Dr. Doria is a Senior Investigator in the Section on Genetics and Epidemiology as well as Co-Director of the Advanced Genomics and Genetics Core at Joslin Diabetes Center. He is also an Associate Professor of Medicine at Harvard Medical School and an Associate Professor in the Department of Epidemiology at the Harvard School of Public Health. He received his medical degree and his doctorate in endocrinology and metabolism from the University of Padua in Italy, and his MPH from the Harvard School of Public Health.The goal of Dr. Doria's research is to identify factors that predispose to the long-term complications of diabetes and use this knowledge to find novel treatments to prevent, stop, or reverse these health problems. To this end, he has developed a research program that draws on the large diabetic population of the Joslin Clinic and applies the tools of epidemiology and genetics.
Dr. Jason Gaglia is a graduate of Rutgers College in New Jersey where he earned degrees in Biochemistry and Microbiology, Biology, Chemistry, and General Physics. He went on to Harvard Medical School as part of the Harvard/Massachusetts Institute of Technology Health Sciences and Technology Program where he was awarded his MD magna cum laude. He also is a graduate the Beth Israel Deaconess Medical Center/Harvard affiliated Clinical Investigator Training Program. He completed residency in Internal Medicine and fellowship in Endocrinology, Diabetes, and Metabolism at Beth Israel Deaconess Medical Center and Joslin Diabetes Center. He is currently the Director of the Hood Center for the Prevention of Childhood Diabetes at Joslin Diabetes Center. In this capacity he leads multiple diabetes clinical trials at Joslin including those under the Type 1 Diabetes TrialNet umbrella.Dr. Gaglia's research has been focused on immunology and type 1 diabetes. His accomplishments in these areas include cloning the immune regulatory molecule TIM-3, being a member of the National Institutes of Health Clinical Islet Transplant Program, and leading a clinical trial demonstrating the feasibility of using magnetic resonance imaging to measure inflammation in the pancreas with the development of type 1 diabetes. Dr. Gaglia is also a practicing Adult Endocrinologist and sees patients at Joslin Clinic.
Dr. Om Ganda is a senior physician and clinical research scientist at Joslin Diabetes Center for many years. He directs the Lipid Clinic at Joslin. His research interests include prevention of cardiovascular outcomes in diabetes. He is an educator for residents, fellows, and at various national and international meetings.
Dr. Laurie J. Goodyear is a graduate of Springfield College in Massachusetts (B.S. in Physical Education, Magna Cum Laude), The University of South Carolina (M.S. in Exercise Physiology), and The University of Vermont (Ph.D. in Cell Biology). She completed her postdoctoral research at Joslin and has been the recipient of several awards including Career Development Awards from the American Diabetes Association and Juvenile Diabetes Foundation, a New Investigator Award from the American College of Sports Medicine, and the 2012 Edward F. Adolph Distinguished Lectureship of the American Physiological Society. She has published more than 175 papers and has had the honor of giving over 100 invited lectures at national and international conferences. She is currently Senior Investigator at the Joslin Diabetes Center where she serves as the co-Head of the Section on Integrative Physiology and Metabolism, the Director of the NIH-funded Diabetes Research Center Animal Physiology Core, and the Acting Director of the recently established Clinical Exercise Physiology Research Laboratory. She is also an Associate Professor in Medicine at Harvard Medical School. Research in the Goodyear laboratory is discovering the underlying molecular mechanisms by which exercise improves overall health, with particular emphasis on metabolic health.
Hamdy Clinical Research Lab is evaluating the short- and long-term effects of weight reduction on several metabolic and cardiovascular outcomes in patients with diabetes. The lab is also studying different models of medical nutrition therapy in relation to weight reduction, diabetes control, body fat distribution and cardiovascular risk factors.
Dr. Edward Horton has been involved in diabetes research since 1964. His primary research interests are in studying insulin resistance, obesity, physical exercise and the regulation of energy balance as they relate to the development of diabetes and its co-morbidities, including both microvascular and cardiovascular diseases. Current major projects are the Diabetes Prevention Program Outcomes Study and the LookAHEAD Study.
Hsu's research interests include determining the causes and optimal treatment approaches
for type 2 diabetes in non-obese individuals, such as in Asian Americans. As his focus evolved from identifying
different features of diabetes in ethnic populations to developing new
solutions, Dr. Hsu aims to develop and test new care models integrating cultural,
physiological and digital health technologies to diabetes care.
Dr. Albert Hwa is the Operations Director for Joslin's Center for Cell-Based Therapy for Diabetes (CCTD). Prior to joining the Joslin Diabetes Center, he was the Director of Discovery Research at JDRF. Dr. Hwa received his B.S. in chemical engineering from Cornell University and his Ph.D. in bioengineering from Massachusetts Institute of Technology. His dissertation focused on liver tissue engineering devices and physiological organ cultures. He serves on grant review panels for JDRF.
C. Ronald Kahn is a world recognized expert in diabetes and obesity research, as well as a preeminent investigator in the area of insulin signal transduction and mechanisms of altered signaling in diabetes and metabolic disease. Dr. Kahn is Senior Investigator, Head of the Section on Integrative Physiology and Metabolism at Joslin Diabetes Center and the Mary K. Iacocca Professor of Medicine at Harvard Medical School. Dr. Kahn served as Research Director of the Joslin Diabetes Center from 1981 to 2000, and served as President of Joslin from 2001 to 2007. He is currently the Center’s Chief Academic Officer.Dr. Kahn has received more than 70 awards and honors, including the highest honors of the American Diabetes Association, U.S. and British Endocrine Societies, Juvenile Diabetes Research Foundation, European Association for the Study of Diabetes and the American Association of Clinical Endocrinologists, and election to the National Academy of Science and Institute of Medicine. He has authored more than 600 original publications and 200 reviews and chapters.Dr. Kahn holds undergraduate and medical degrees from the University of Louisville. He also holds an honorary Master of Science from Harvard University, honorary Doctor of Science degrees from the University of Paris, University of Louisville, University of Geneva and Washington University in St. Louis, an honorary Doctor of Medicine from the University of Copenhagen and is an honorary Professor and Director of the Diabetes Center at Peking University School of Medicine.
My laboratory studies the mechanism by which hyperglycemia, diabetes and insulin resistance are causing diabetic retinopathy, nephropathy and cardiovascular diseases.
Dr. Kissler received his B.Sc. in Biochemistry and his Ph.D. in Immunology from the University of Bristol, UK. Following postdoctoral work at the Dana-Farber Cancer Institute in Boston and at the Massachusetts Institute of Technology in Cambridge, MA, Dr. Kissler was appointed to a group leadership at the Rudolf Virchow Center at the University of Wurzburg, Germany, in 2007. In April 2012, Dr. Kissler returned to Boston to join the section for Immunobiology at the Joslin Diabetes Center, where his laboratory investigates the function of type 1 diabetes genes.
Originally from Canada, Dr. Kostic did his undergraduate work at the University of Toronto and then received his Ph.D. in the program in Biological and Biomedical Sciences at Harvard Medical School. He conducted his postdoctoral work at the Broad Institute. His research has earned him several distinctions including a Helen Hay Whitney Fellowship, the Lawrence H. Summers Fellowship, and a spot on the annual Forbes Magazine 30 Under 30 list.
Dr. Krolewski heads the Section on Genetics and Epidemiology and is a Professor of Medicine at Harvard Medical School. He received his MD and PhD from Warsaw Medical University in Poland. He obtained training in diabetes research at Joslin Diabetes Center and in molecular human genetics at Massachusetts Institute of Technology.Drawing upon the large Joslin Clinic patient
population, Dr. Krolewski has established a world-renowned multi-disciplinary research
laboratory that combines epidemiologic, genetic and proteomic methods to study the
causes of kidney complications (diabetic nephropathy) in Type 1 and Type 2
diabetes and how to diagnose and treat them.
The Kulkarni lab is focused on differentiating
induced pluripotent stem cells to generate insulin-producing cells.
Complementary studies are aimed at identifying endogenous/exogenous proteins
that can be targeted with the long-term goal of enhancing functional beta cells
to treat and/or cure type 1, type 2, and gestational diabetes.
Lori Laffel, MD, MPH, focuses her research on preventing the late complications of type 1 and type 2 diabetes and preserving the health, normal growth, development and family functioning of children, adolescents, and young adults with diabetes. The large pediatric research program, led by Dr. Laffel, provides many opportunities for pediatric patients and families to participate in clinical investigations at Joslin.
Jongsoon Lee, Ph.D., is an Assistant Investigator in the Section on Pathophysiology and Molecular Pharmacology at Joslin and an Assistant Professor of Medicine at Harvard Medical School. Dr. Lee received his BS and MS degrees from Seoul National University in Korea. He received his Ph.D. in Biochemistry from Boston University School of Medicine. The major interest of Dr. Lee's lab is to determine the roles immune cells play in the development of obesity-induced inflammation and insulin resistance. In particular, his lab studies the immunological functions of adipose tissue immune cells in obesity and their effects on metabolic diseases including type 2 diabetes and cardiovascular diseases.
Physical exercise is critical for maintaining a healthy skeletal muscle mass and promoting whole body health and longevity. Dr. Lessard's primary research focus is to determine how exercise-stimulated morphological adaptations in skeletal muscle contribute to the prevention and treatment of chronic metabolic disease.
Dr. Lipes is a physicial-scientist who received her medical degree from McGill University in Montreal. After completing her residency training in Pediatrics, she was a Medical Staff Fellow in the Endocrinology Program and a Research Associate in the Cell Biology and Metabolism Branch at the National Institutes of Health. Since joining Joslin Diabetes Center, she has been the recipient of numerous awards and honors, including the Mary K. lacocca Faculty Fellowship, a Smith Family Foundation New Investigator and the Charles H. Hood Child Health Research Award. She has also served as a standing member of the NIDDK Cellular Aspects of Diabetes and Obesity (CADO) study section (2007-11).
Dr. Loeken studies how excessive glucose metabolism, caused by maternal diabetes, disturbs the metabolic cues that control proliferation and cell fate during embryonic development. Her lab uses embryonic stem cells, induced pluripotent stem cells, and mouse models in order to understand the molecular causes of birth defects, especially neural tube defects, caused by diabetic pregnancy.
Dr. Mehta's research focuses on the healthcare delivery and clinical outcomes for individuals with type 1 and type 2 diabetes. He leverages large clinical and research databases to evaluate the clinical-effectiveness of care models at Joslin and across the U.S.
Dr. Patti received her undergraduate and medical
degrees through an accelerated medical school program at Jefferson Medical
College, followed by internal medicine residency at the University of
Pittsburgh, and training in the joint Harvard Medical School endocrinology
fellowship program. She is currently Investigator, Co-Director of the Joslin
Advanced Genetics and Genomics Core, Director of the Hypoglycemia Clinic (all
at Joslin Diabetes Center), and Associate Professor of Medicine, Harvard
Medical School. Dr. Patti has served on many volunteer leadership roles within
the American Diabetes Association. She was elected to the American Society of
Clinical Investigation in 2009 and to Fellowship in both the Obesity Society
and American College of Physicians in 2014. The primary focus of the Patti Laboratory is to identify the molecular and metabolic pathways which are disrupted in individuals at risk for diabetes. We are particularly interested in mechanisms by which environmental or nutritional factors can mediate risk, potentially by altering transcriptional regulation and metabolism at a cellular level, and how risk can be transmitted from one generation to the next via epigenetic mechanisms.
Rask-Madsen lab studies the relationship between obesity, diabetes and cancer. Our focus is on how dysfunction vascular cells may promote tumor formation. We believe that endothelial cell dysfunction can increase cancer development by contributing to chronic inflammation or create a supporting vascular niche for cancer stem cells.
Marilyn Ritholz is an Assistant Professor of Psychology
at Harvard Medical School. She received her BA degree from University of
California, Berkeley and her PhD from University of Wisconsin, Madison. She is
a clinician-researcher in the Weinger lab who studies the psychosocial aspects
of diabetes through qualitative research. Her research focuses on the
patient-provider relationship in diabetes, psychosocial aspects of diabetes
technology, and patients' perceptions of providers' communication about diabetes
Sylvia E. Rosas, MD, MSCE is currently the director of the Latino Kidney Clinic at the Joslin Diabetes Center. She completed her nephrology and epidemiology training at the University of Pennsylvania.
Type 1 diabetes results from an autoimmune T cell attack beta cells within the pancreas. The research efforts of the Serwold lab focus on identifying key steps in the development of both normal and autoimmune T cells, on detecting autoimmune T cells in ongoing disease, and on developing novel approaches for preventing autoimmune T cell development.
The Shoelson lab identifies physiological and pathological mechanisms
amenable to being targeted for the development of potential new therapies for
diabetes and its complications. The proteins and pathways currently being
targeted include inflammation, AMPK, mTOR and HSF1.
Dr. Silva is a staff ophthalmologist and assistant
chief of telemedicine at the Beetham Eye Institute of the Joslin Diabetes
Center as well as Assistant Professor of Ophthalmology at Harvard Medical
School. His work is focused on innovative and investigative work at a field
that is at the intersection of clinical care and technology with the hope of
providing an ideal model for the delivery of evidence based highly effective
and efficient diabetes eye care to the population that needs it the most. Dr.
Silva’s primary expertise lies in the fields of ocular telehealth for diabetic
retinopathy, ultrawide field retinal imaging and electronic medical record
Robert C. Stanton's research is focused on an
essential enzyme that plays an essential role in regulating oxidative stress
and many other functions in all cells, glucose 6-phosphate dehydrogenase
(GDP6). His lab has discovered that this enzyme is essential for cell survival
and plays an important role in the pathogenesis of a variety of diseases
including diabetes and diabetic complications.
Dr. Sun is a vitreoretinal surgeon and Chief of the Center for Clinical
Eye Research and Trials of the Beetham Eye Institute, Joslin Diabetes Center. She is an Associate Professor of Ophthalmology at Harvard Medical School. She also serves as the nationwide Protocol Working Investigator for the
Diabetic Retinopathy Clinical Research Network (DRCR.net) and has chaired
several nationwide, multicenter studies addressing new treatments and methods
of evaluation for diabetic eye disease. Her research projects include the
search for biomarkers of functional and anatomic outcomes in diabetic
retinopathy and diabetic macular edema through utilization of advanced retinal
Tseng is an Associate Professor of Medicine at the Harvard Medical School and a
Principal Investigator in the Section on Integrative Physiology and Metabolism
at the Joslin Diabetes Center. She received her doctorate in Developmental
Biology and Cellular and Molecular Biology from the University of
Wisconsin-Madison and completed postdoctoral training at Joslin Diabetes
Center, Harvard Medical School. Dr. Tseng was an Eleanor and Miles Shore
Scholar in Medicine at Harvard Medical School. She serves, or has served on,
the grant review panels for the National Institutes of Health, the American
Diabetes Association, the Department of Defense, the U.S. Army Medical Research
and Material Command, and the European Research Council.
Wagers’ research seeks to understand how changes in stem cell activity impact
tissue homeostasis and repair throughout life, and how these cells may be
harnessed for regenerative medicine. Amy Wagers is a Senior Investigator in the Section on Islet Cell and Regenerative Biology at the Joslin Diabetes Center, the Forst Family Professor of Stem Cell and Regenerative Biology at Harvard University, and a member of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School. Dr. Wagers received her Ph.D. in Immunology and Microbial Pathogenesis from Northwestern University and completed her postdoctoral training in stem cell biology at Stanford University. Dr. Wagers has authored more than 100 primary research and review articles, and her work has been recognized by awards from the Burroughs Wellcome Fund, Beckman Foundation, HHMI and National Institutes of Health. In 2013, she received the New York Stem Cell Foundation's Robertson Prize for outstanding achievement in translational stem cell research, and she is the 2015 recipient of the Vincent Cristofalo Rising Star in Aging Research Award.
Gordon Weir M.D. is the Co-Head of Joslin's Section on Islet and Regenerative Biology, holds the Diabetes Research and Wellness Foundation Chair at Joslin, and is Professor of Medicine at Harvard Medical School. Dr. Weir received his medical degree from Harvard Medical School. Dr. Weir's research has focused on pancreatic islets, in particular on the function of islets in the normal and diabetic state, on beta cell replacement therapies, on protection of beta cells from immune destruction by encapsulation and other means, and on developing alternative sources of insulin-producing cells.
Joslin Diabetes Center today announced that Peng Yi, Ph.D., has been appointed an Assistant Investigator in the Islet Cell and Regenerative Biology Section of Joslin’s Research Division. Yi joins a leading team of researchers focused on improving diabetes treatment and finding a cure.